Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/cdb53169-f08e-4509-9fef-82424c1bca56/

RGO

Regeneron Pharmaceuticals, Inc.
Chart
€551.40
Latest Week 2026-06-05
HealthcareBiotechnologyLARGE
Snapshot 2026-06-07 · 0.0w · Fresh
0.76
OS Score
61.0%
Value
73.0%
Quality
46.0%
Momentum
5/9
F-Score
0.667
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
4 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
QV 0.667
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
10.0%
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
Noneyr
🌱
GARP
✗
🔄
Shareholder Yield
5.9%
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
61.0%ile
P/E
13.1×
P/S
3.9×
P/B
1.8×
E/P
0.0764
FCF Yield
0.066
EBITDA/EV
0.100
SH Yield
0.059
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
60.00000000
/100 — 1=cheapest
VC2 (Trending Value)
41.00000000
/100
VC3 (Buyback)
44.00000000
/100
FCF yield of 6.6% is strong — the business generates significant free cash relative to price.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
73.0%ile
ROE
0.141
ROA
0.108
Net Margin
0.296
Op Margin
0.257
GPA
0.309
Current
3.57
F-Score
5/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.010
Earn Growth
0.059
Stability
0.334
lower=better
Accruals
-0.014
lower=better
5yr Consist
Yes
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
46.0%ile
6M Return
-10.5%
Vol 252d
42.5%
Vol 60d
93.5%
↑ Expanding
Max DD 12M
-30.5%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
Near-term vol (94%) is expanding vs long-term (42%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.76
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 79 peers
Sector Value %ile
76.2%
Sector Quality %ile
62.5%
P/E z-score
-0.60
P/B z-score
-0.41
Sector Avg OS
49.0%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
MED MEDICLIN Aktiengesellschaft 99.0% 97.0% 83.0% 79.0%
DRW8 Drägerwerk AG & Co. KGaA 96.0% 93.0% 62.0% 78.0%
DRW3 Drägerwerk AG & Co. KGaA 95.0% 85.0% 62.0% 80.0%
AJ91 DocCheck AG 95.0% 82.0% 88.0% 70.0%
CBHD Coloplast A/S 94.0% 98.0% 91.0% 22.0%
M12 M1 Kliniken AG 93.0% 70.0% 89.0% 76.0%
BRM Bristol-Myers Squibb Company 92.0% 61.0% 98.0% 74.0%
NOV Novo Nordisk A/S 91.0% 98.0% 78.0% 20.0%
Factor Interactions
Strong Capital Return
Shareholder yield 5.9% backed by 6.6% FCF yield. Returns are well-funded.
Volatility Expanding
60-day vol (94%) significantly exceeds 252-day (42%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
B
68.4% avg (7 factors)
Quality
B
72.8% avg (7 factors)
Momentum
F
24.3% avg (1 factors)
Risk
C
45.9% avg (1 factors)
This stock sits in the O'Shaughnessy sweet spot — cheap AND high quality. Historically, this combination has generated the strongest long-term returns. Momentum is weak, suggesting the market isn't yet buying this thesis. Patience required.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Factor Persistence1 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.760—1—
Value %ile0.610—0—
Quality %ile0.730—1—
Momentum %ile0.460—0—
F-Score5.000—0—
Confidence0.879—1—
Volatility0.425—1—
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
13.09
Earnings Yield (E/P)
0.0764
Price / Sales
3.88
Price / Book
1.84
Price / Cash Flow
11.55
FCF Yield
6.6%
EBITDA / EV
10.0%
Sales Yield (1/P·S)
0.2588
Shareholder Yield
Div + net buyback / mktcap
5.9%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
14.1%
Return on Assets
10.8%
Net Margin
29.6%
Operating Margin
25.7%
Gross Profit / Assets
Novy-Marx GPA
30.9%
Current Ratio
3.57
Accruals Ratio
(NI-OCF)/Assets — lower=better
-0.014
External Financing
Net issuance — lower=better
0.111
MomentumPrice trend strength over different horizons
6M Return
-10.5%
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
1.0%
Earnings Growth (YoY)
5.9%
Earnings Stability (CV)
Lower = more stable
0.334
5yr Consistent
EPS up every year for 5 years
Yes
Piotroski F-Score
5
Dividend Yield
0.6%
Buyback Yield
5.3%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
60
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
41
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
44
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity